A drug-eluting article which is selected from the group consisting of a stent, a stent graft, an anastomosis device, a vascular graft, and a vascular patch, comprising: a substrate; a first polymeric layer coated over said substrate, wherein said first polymeric layer comprises at least a first biocompatible polymer which is biodegradable, and at least a first pharmacologically active compound that is encapsulated in the first biocompatible polymer; a second polymeric layer formed over said first polymeric layer, wherein said second polymeric layer comprises at least a second biocompatible polymer and wherein the first polymeric layer is configured as an intermediate coating layer between the second layer and the substrate, in which each of the first biocompatible polymer and the second biocompatible polymer is the same member of the group consisting of polylactic acid, polyglycolic acid, and copolymers of lactic acid and glycolic acid (PLGA), in which the molecular weight or the crystallinity or each of the molecular weight and the crystallinity of the second biocompatible polymer is lower than that of the first biocompatible polymer so that the second biocompatible polymer has a higher degradability than the first biocompatible polymer; wherein when the first pharmacologically active compound is hydrophilic, the first biocompatible polymer is hydrophilic and when the first pharmacologically active compound is hydrophobic, the first biocompatible polymer is hydrophobic; wherein degradability is the rate of resorption of the biocompatible polymers of an implanted article and higher degradability refers to a faster resorption rate, or a shorter period of time that is needed to complete the resorption process. a substrate; a first polymeric layer coated over said substrate, wherein said first polymeric layer comprises at least a first biocompatible polymer which is biodegradable, and at least a first pharmacologically active compound that is encapsulated in the first biocompatible polymer; a second polymeric layer formed over said first polymeric layer, wherein said second polymeric layer comprises at least a second biocompatible polymer and wherein the first polymeric layer is configured as an intermediate coating layer between the second layer and the substrate, in which each of the first biocompatible polymer and the second biocompatible polymer is the same member of the group consisting of polylactic acid, polyglycolic acid, and copolymers of lactic acid and glycolic acid (PLGA), in which the molecular weight or the crystallinity or each of the molecular weight and the crystallinity of the second biocompatible polymer is lower than that of the first biocompatible polymer so that the second biocompatible polymer has a higher degradability than the first biocompatible polymer; wherein when the first pharmacologically active compound is hydrophilic, the first biocompatible polymer is hydrophilic and when the first pharmacologically active compound is hydrophobic, the first biocompatible polymer is hydrophobic; wherein degradability is the rate of resorption of the biocompatible polymers of an implanted article and higher degradability refers to a faster resorption rate, or a shorter period of time that is needed to complete the resorption process.